Xenografting for disease modeling of intramedullary spinal cord tumors: a systematic review
Xenografting for disease modeling of intramedullary spinal cord tumors: a systematic review
复制标题
DOI：
10.1038/s41393-019-0248-6
复制
发表时间：
2019-02
期刊：
影响因子：
2.2
通讯作者：
L. Rauschenbach;E. Kocakavuk;D. Pierscianek;Yahya Ahmadipour;S. Kebir;Martin Glas;Björn Scheffler;Ulrich Sure;R. Jabbarli
中科院分区：
文献类型：
--
作者：
L. Rauschenbach;E. Kocakavuk;D. Pierscianek;Yahya Ahmadipour;S. Kebir;Martin Glas;Björn Scheffler;Ulrich Sure;R. Jabbarli
研究设计系统回顾。目的髓内脊髓肿瘤（IMSCT）的总体发病率仍然较低，并且缺乏临床试验或标准化治疗策略。因此，开发了多种基于动物的异种移植模型（AXM）来促进 IMSCT 的临床前研究工作。我们构建了系统文献综述，以总结和比较 2018 年 4 月 16 日之前发布的 IMSCT 的所有 AXM。 方法 该综述是使用 4 个独立研究数据库遵循 PRISMA（系统评价和荟萃分析的首选报告项目）指南进行的。如果研究报告了肿瘤细胞或肿瘤组织手术移植到脊髓，则被纳入其中。方法学研究质量根据SYRCLE（实验动物实验系统审查中心）风险偏差工具进行评估。结果系统检索产生了20篇涉及IMSCT AXM的出版物。总之，在 23 项实验中使用约 337 只动物对 4 个肿瘤实体进行了分析，主要研究胶质母细胞瘤或胶质肉瘤生物学。关于移植动物的使用、手术技术和肿瘤负荷的研究各不相同。最常见的作者使用异位、经硬膜将永生化脑肿瘤细胞系（1 × 105in 5 μl）注射到免疫功能低下大鼠的胸脊髓中。质量评估表明在大多数情况下存在不明确的偏倚风险。结论尽管迄今为止已经描述了用于 IMSCT 的不同 AXM，但一种大鼠模型在技术上是可行的，可以进行稳健的实验并展示可重复的结果。然而，需要使用患者来源的肿瘤细胞的原位移植的新型 AXM 和基因工程动物模型。
Study designSystematic review.ObjectivesThe overall incidence of intramedullary spinal cord tumors (IMSCT) remains low and clinical trials or standardized treatment strategies are missing. Therefore, multiple animal-based xenograft models (AXM) have been developed to foster preclinical research efforts on IMSCT. We constructed a systematic literature review to summarize and compare all AXM for IMSCT, published until April 16, 2018.MethodsThe review was conducted using 4 independent research databases following the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines. Studies were included, if they reported on surgical transplantation of tumor cells or tumor tissue to the spinal cord. Methodological study quality was assessed according to the SYRCLE (systematic review center for laboratory animal experimentation) risk of Bias tool.ResultsSystematic search yielded 20 publications dealing with AXM for IMSCT. In summary, 4 tumor entities were analyzed in 23 experiments using ~337 animals, mainly investigating glioblastoma or gliosarcoma biology. Studies varied regarding the use of engrafted animals, surgical techniques and tumor burden. Most commonly authors used heterotopic, transdural injection of immortalized brain tumor cell lines (1 × 105in 5 µl) into the thoracic spinal cord of immunocompromised rats. Quality assessment demonstrated an unclear risk of bias in most cases.ConclusionAlthough different AXM for IMSCT have been described so far, one rat model is technically feasible, enables robust experiments and demonstrates reproducible results. However, there is a need for new AXM using orthotopic engraftment of patient-derived tumor cells and for genetically engineered animal models.